| Julian Claus Fagerli, MD | |
|
155 Riverbend Dr, Charlottesville, VA 22911-8607 | |
| (434) 295-0184 | |
| (434) 295-2463 |
| Full Name | Julian Claus Fagerli |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 30 Years |
| Location | 155 Riverbend Dr, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538148259 | NPI | - | NPPES |
| 432285 | Other | ANTHEM/BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 0101225461 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Martha Jefferson Hospital | Charlottesville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Urological Associates, Ltd | 0446232573 | 5 |
| Piedmont Stone Center Pllc | 2961315718 | 61 |
News Archive
A new study found the use of outdoor parks and trails in urban areas of North Carolina declined during two summer months of 2020 – contrary to anecdotal reports of a spike in new users during the COVID-19 pandemic.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.
Today's headlines include a report that health law opponents want to add plaintiffs to their lawsuit as well as dispatches from the GOP primary election compaign trail.
› Verified 1 days ago
| Entity Name | Piedmont Stone Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700827409 PECOS PAC ID: 2961315718 Enrollment ID: O20031124000526 |
News Archive
A new study found the use of outdoor parks and trails in urban areas of North Carolina declined during two summer months of 2020 – contrary to anecdotal reports of a spike in new users during the COVID-19 pandemic.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.
Today's headlines include a report that health law opponents want to add plaintiffs to their lawsuit as well as dispatches from the GOP primary election compaign trail.
› Verified 1 days ago
| Entity Name | Urological Associates, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700810397 PECOS PAC ID: 0446232573 Enrollment ID: O20040603000110 |
News Archive
A new study found the use of outdoor parks and trails in urban areas of North Carolina declined during two summer months of 2020 – contrary to anecdotal reports of a spike in new users during the COVID-19 pandemic.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.
Today's headlines include a report that health law opponents want to add plaintiffs to their lawsuit as well as dispatches from the GOP primary election compaign trail.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julian Claus Fagerli, MD 155 Riverbend Dr, Charlottesville, VA 22911-8607 Ph: (434) 295-0184 | Julian Claus Fagerli, MD 155 Riverbend Dr, Charlottesville, VA 22911-8607 Ph: (434) 295-0184 |
News Archive
A new study found the use of outdoor parks and trails in urban areas of North Carolina declined during two summer months of 2020 – contrary to anecdotal reports of a spike in new users during the COVID-19 pandemic.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.
Today's headlines include a report that health law opponents want to add plaintiffs to their lawsuit as well as dispatches from the GOP primary election compaign trail.
› Verified 1 days ago
Dr. Kirsten Greene, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-244-9481 | |
Mikel Gray, N.P. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr Fl 3, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-982-3652 | |
Jacqueline Marie Zillioux, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-244-9481 | |
Ryan P. Smith, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-982-3652 | |
Stephen H. Culp, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-244-9481 | |
Adel B. Guirguis, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: Uva Hospital W, Hospital Drive, Charlottesville, VA 22908 Phone: 434-924-2224 Fax: 434-243-6878 | |
Dr. Frazier T Fortenberry Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 630 Peter Jefferson Pkwy, Suite 135, Charlottesville, VA 22911 Phone: 434-244-5722 Fax: 434-244-5723 |